In this Review, the authors describe the relationships between persistent DNA damage, inflammation and cellular senescence, which represent a common pathway that contributes to the pathology of many conditions, including rheumatic diseases.

Sarcopenia, which involves the generalized loss of skeletal muscle strength and mass, is commonly associated with rheumatoid arthritis. In this Review, the authors discuss the epidemiology, pathophysiology and identification of rheumatoid sarcopenia and present evidence for the therapeutic roles of physical activity, nutrition and pharmacotherapy.

This Evidence-Based Guideline presents the latest treatment recommendations for medication selection in psoriatic arthritis (PsA), covering the six clinical domains of PsA, related conditions and associated comorbidities, and reflecting important advances in the field since the previous update.

In a large cohort of patients with psoriasis, treatment with biologic DMARDs targeting the IL-23 pathway was associated with a reduced risk of developing inflammatory arthritis as compared with anti-TNF treatment.

Protein phosphatase magnesium-dependent 1A is a negative modulator of transforming growth factor β signalling and a potential new therapeutic target in osteoarthritis.